5:48 PM
 | 
Jun 20, 2013
 |  BC Extra  |  Clinical News

Celgene reports Phase II data for Revlimid in lymphoma

Celgene Corp. (NASDAQ:CELG) presented data on Thursday at the Malignant Lymphoma meeting in Lugano from a pair of Phase II trials evaluating the company's multiple myeloma (MM) drug Revlimid lenalidomide in lymphoma patients. In the Phase II ALLIANCE (CALGB-50803) trial to treat previously untreated follicular lymphoma, once-daily oral Revlimid plus rituximab led...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >